Kymera
degrading degrader advantage | Kymera
Company
Deck Type
Sector
Industry
Deck date
December 2022
Slide
24 of 63
Similar slides by Kymera
See diffirences between slides (animation)
Investor Presentation
December 2023
degrading best approach to block driven inflammation degrader advantage | Kymera
Investor Presentation
November 2023
degrading best approach to block driven inflammation | Kymera
Investor Presentation
August 2023
degrading best approach to block driven inflammation on | Kymera
Investor Presentation
June 2023
degrading best approach to block driven inflammation on | Kymera
Related slides by other companies
BenevolentAI
Investor Presentation
October 2022
portfolio key in points ben atopic dermatitis ben ulcerative colitis ben pipeline depth and progression inflection | BenevolentAI
AstraZeneca
Results
February 2024
highlights accelerating our ambition in immune mediated diseases innovative immunology portfolio investing in cell therapies with curative potential | AstraZeneca
BenevolentAI
Investor Day
September 2022
ben atopic dermatitis atopic dermatitis is the most common chronic in skin disease characterized by intensely itchy red and swollen skin affects of children and up to of adults approximately of all cases present with mild moderate disease severity prevalence is rising with market value in forecast to exceed billion skin in and chronic pruritus associated with atopic dermatitis negatively impact quality of life and psychosocial well being clear unmet need in mild to moderate patient segment for treatment addressing itch and in without side effects of steroids | BenevolentAI
BenevolentAI
Investor Day
September 2022
ben a potent antagonist developed to relieve in and provide rapid itch resolution atopic dermatitis ben is a inhibitor targeting and receptors the receptors were as part of an effort to mediators of both itch and in in using our molecular design we were able to design a inhibitor equipotent against the receptors ben is expected to treat atopic dermatitis by inhibiting itch signaling and blocking nerve sensitization in addition to inhibiting and mediated dermal in ben will target mild moderate and severe atopic dermatitis patients addressing unmet need in the treatment of mild to moderate atopic dermatitis as a steroid sparing alternative and in more severe patients undergoing treatment with that require add on treatment | BenevolentAI
Other recent decks by Kymera
See all presentations (7 decks)
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io